Insmed Incorporated (INSM) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Bridgewater, NJ, United States. The current CEO is William H. Lewis.
INSM has IPO date of 2000-06-01, 1,271 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $33.07B.
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company's commercial product, ARIKAYCE, is an inhaled antibiotic combination therapy approved for treating Mycobacterium avium complex lung disease in adults. Insmed's pipeline includes Brensocatib, an oral inhibitor of dipeptidyl peptidase 1 being developed for bronchiectasis and neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treatment candidate for pulmonary arterial hypertension and other rare pulmonary disorders. Founded in 1988 and headquartered in Bridgewater, New Jersey, the company specializes in addressing unmet medical needs in rare respiratory and systemic diseases.
